Clinical Trials@2x
  • News

    Most Read

    • Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial
    • Moderna begins dosing in Covid-19 vaccine study in Japan
    • Reify Health extends StudyTeam platform availability for clinical trials

    Most Recent

    Clinical Trials

    Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial

    22 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
    • Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
    • Novo Nordisk’s makes strides into Alzheimer’s with anti-diabetic drug

    Most Recent

    Clinical Trials

    Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

    12 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices

    Most Read

    • Global clinical trials activity increases 14.0oY in Q4 2020
    • Total number of Covid-19 clinical trials continues to rise as cases and deaths rise
    • Orphazyme’s arimoclomol expected to be used with Zavesca after likely FDA approval in Niemann-Pick disease type C

    Most Recent

    Global clinical trials activity increases 14.0oY in Q4 2020

    22 Jan 2021
  • Themes
  • Deals

    Most Read

    • Investment firm GI Partners closes Clinical Ink acquisition
    • Investment firm GI Partners to acquire minority interest in Clinical Ink
    • IVI and SNU partner to trial Inovio’s Covid-19 vaccine in Korea

    Most Recent

    Clinical Trials

    Investment firm GI Partners closes Clinical Ink acquisition

    27 Aug 2020
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • Linari NanoTech
    • OpenClinica
    • Strategikon Pharma

    Most Recent

    Linari NanoTech

    19 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices
  • Deals
  • Tech
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
EHP starts enrolment in EHP-101 Phase I trial for MS and scleroderma

EHP starts enrolment in EHP-101 Phase I trial for MS and scleroderma

Emerald Health Pharmaceuticals (EHP) has started patient enrolment for its Phase I clinical trial of...

28th September 2018

Latest News

Clinical Trials

Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial

22 Jan 2021
Clinical Trials

Moderna begins dosing in Covid-19 vaccine study in Japan

22 Jan 2021
Clinical Research

Reify Health extends StudyTeam platform availability for clinical trials

21 Jan 2021
Clinical Trials

Forma doses first patient in Phase I prostate cancer treatment trial

21 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
Clinical Trials

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more